Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

@article{Brada1999PhaseID,
  title={Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies},
  author={Michael Brada and Ian Judson and Philip J. Beale and Sally Falk Moore and Pascale Reidenberg and Paul Statkevich and M T Dugan and Vineet Batra and David L. Cutler},
  journal={British Journal of Cancer},
  year={1999},
  volume={81},
  pages={1022 - 1030}
}
SummaryTemozolomide, an oral cytotoxic agent with approximately 100% bioavailability after one administration, has demonstrated schedule-dependent clinical activity against highly resistant cancers. Thirty patients with minimal prior chemotherapy were enrolled in this phase I trial to characterize the drug’s safety, pharmacokinetics and anti-tumour activity, as well as to assess how food affects oral bioavailability. To determine dose-limiting toxicities (DLT) and the maximum tolerated dose… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 86 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 1997
View 6 Excerpts
Highly Influenced

Blockade of base excision repair ap to mediate cytotoxicity to temozolomide in mismatch repair deficient tumo cells [abstract 1536

L Liu, S Chatterjee, SL Gerson
Proc Am Assoc Cancer Res • 1997
View 1 Excerpt

In vivo demonstration

CS Brock, JC Matthews, G Brown, ES Newlands, P Price
1997

In vivo demonstration of 11 C - temozolomide uptake by human recurrent high - grade astrocytomas [ abstract ]

CS Brock, JC Matthews, G Brown, ES Newlands, P Price
Br J Cancer • 1997

Similar Papers

Loading similar papers…